June 24, 2025 — On the closing day of the ADA Scientific Sessions in Chicago, we got a good look at two remarkable new obesity drugs. Both of them have potential to bring important advances. Both of them need more work before they will be ready to go to FDA for approval. This was a rare treat. Bimagrumab The […]
June 23, 2025 — With two new publications in the New England Journal of Medicine, we are thinking that CagriSema has something to teach us about using weight loss outcomes to judge the merits of a new obesity medicine. Is more always better? Researchers presented the data from these two pivotal clinical trials on CagriSema at the ADA Scientific […]
June 22, 2025 — We are only halfway through ADA2025 in Chicago and already the flood of information about new drugs for obesity like orforglipron, amycretin, and a host of others leaves us feeling like we have been sprayed down by a fire hose. Much more will be coming at us in the next two days. Orforglipron and Other […]
June 21, 2025 — “It takes a village to create standards of care,” said Nuha Ali El Sayed as she opened a symposium on the emerging standards of care for obesity. Truer words were never spoken. Defining these standards is tricky. That’s because they they need to reflect both what is desirable and a standard that good health professionals […]
June 20, 2025 — We are landing in Chicago for the ADA Scientific Sessions and you can be sure that a veritable river of news about obesity will be flowing. Everything from basic science to innovative treatment and pragmatic approaches for clinical care and policy will be offered up by this meeting of the American Diabetes Association. This promises […]
June 19, 2025 — In drug therapy for obesity, all of the excitement about GLP-1s and now amylin analogs has focused on regulation of eating behaviors. But, in fact, this is just one part of the process for regulating metabolic function and adiposity. Until now, we have seen little success in developing safe and effective medicines that alter the […]
June 17, 2025 — While much of the public has focused on the remarkable effects of GLP-1 agonists for many people living with obesity, an even more remarkable story has largely escaped notice. In March, FDA approved the first ever treatment for Prader-Willi syndrome. This drug, an extended-release form of diazoxide choline, is transforming the lives of families of […]
June 16, 2025 — Reject the binary. This cry is a response to simplistic, dichotomous thinking that seems to be ruling the day in so many contexts right now. It’s taking us on quite a number of dead-end journeys. One of these is the false dichotomy that suggests we must choose between providing care for obesity or for disordered […]
June 15, 2025 — The previously unquestioned American leadership in science is evaporating. Groundbreaking medical research is stopping abruptly. Research institutes at NIH are disappearing. As this unfolds, the response of many people in supposed roles of scientific leadership has been to duck and take cover. Tell us when it’s over and we can get back to work. Yes, […]
June 14, 2025 — As the upcoming Scientific Sessions for the American Diabetes Association draws closer, the drumbeat for amycretin as a promising new therapy for obesity is growing louder. At the meeting, Novo Nordisk plans to present two different studies to strengthen the case for this novel dual agonist. It targets both GLP-1 and amylin receptors. Then yesterday […]
